N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

Completed · Phase 1

Conditions studied: Neuroblastoma

In brief

RATIONALE: Drugs used in chemotherapy, such as fenretinide LXS, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide LXS in treating patients with recurrent, refractory, or persistent neuroblastoma.

Key facts

Study ID: NCT00295919
Run by: New Approaches to Neuroblastoma Therapy Consortium
People needed: 80
Starts: 2005-12-01
Expected to finish: 2015-05-01
Last updated by the study team: 2026-04-14

Who can join

Age: any, up to 30. Sex: any. Healthy volunteers: not accepted.

Where it is running

Childrens Hospital Los Angeles — Los Angeles, California, United States
Lucile Packard Children's Hospital at Stanford University Medical Center — Palo Alto, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus — Atlanta, Georgia, United States
University of Chicago Comer Children's Hospital — Chicago, Illinois, United States
Children's Hospital Boston — Boston, Massachusetts, United States
C.S. Mott Children's Hospital at University of Michigan Medical Center — Ann Arbor, Michigan, United States
Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
Cook Children's Medical Center - Fort Worth — Fort Worth, Texas, United States
Children's Hospital and Regional Medical Center - Seattle — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.